Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
For Immediate Release
Chicago, IL – August 29, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. V, AstraZeneca PLC AZN, The Walt Disney Co. DIS, FitLife Brands, Inc. FTLF and Utah Medical Products, Inc. UTMD.
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Linde, AstraZeneca and Walt Disney Co.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. , AstraZeneca PLC and The Walt Disney Co. , as well as two micro-cap stocks FitLife Brands, Inc. and Utah Medical Products, Inc. . The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Visa have gained +4.6% over the year-to-date against the Zacks Financial Transaction Services industry’s gain of +7.9%. The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving its revenues. Visa, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth.
The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
However, elevated operating expenses pose margin challenges. It is witnessing a volatile cash volume from the Asia Pacific and CEMEA regions. Consumer spending growth is also drying up. Moreover, rising client incentives will affect its adjusted revenues. As such, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
AstraZeneca’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+32.3% vs. +29.1%). The company has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.
AstraZeneca’s pipeline is strong, with important late as well as mid-stage pipeline data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets.
Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. By 2030, it expects to generate $80 billion in total revenues. However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit.
(You can read the full research report on AstraZeneca here >>>)
Shares of Walt Disney have outperformed the Zacks Media Conglomerates industry over the year-to-date period (+0.3% vs. +0.1%). The company’s third-quarter fiscal 2024 results reflect growth in Disney+ subscribers and theme park and resort businesses.
Recent attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Park in Paris, as well as the Zootopia theme land at Shanghai Disney, are expected to boost the prospects of the theme park business.
At the same time, the company’s declining ad revenues due to fewer impressions have been a headwind for some time now. Disney+’s profitability is expected to be hurt by higher investments in content, which will also increase programming and production costs in the Media and Entertainment Distribution segment. Its leveraged balance sheet remains a concern. Disney+ is facing tough competition from the likes of Netflix and Amazon Prime Video.
(You can read the full research report on Walt Disney here >>>)
FitLife Brands’ shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+74.5% vs. +12.7%). This microcap company with market capitalization of $152.62 million have witnessed 14.7% year-over-year revenue increase in second-quarter 2024, driven by a 17.5% rise in wholesale and 13.3% in online sales.
Strategic acquisitions and a shift to online channels, now two-thirds of revenue, boosted margins to 44.8%. Key acquisitions like Mimi’s Rock and MusclePharm contribute to growth, with MusclePharm revenues up 27.3% sequentially and Mimi’s Rock’s gross margin at 48.2%, though integration risks remain. The company’s low net debt of $11.7 million supports financial flexibility.
However, challenges include declining legacy brand revenues, a 2.2% drop in the MRC segment, and heavy reliance on online sales, posing risks if e-commerce trends shift. High debt and competition in a saturated market also pose concerns.
(You can read the full research report on FitLife Brands here >>>)
Shares of Utah Medical Products have underperformed the Medical - Products industry over the past six months (-0.2% vs. +7.0%). This microcap company with market capitalization of $236.34 million is facing challenges from declining revenues, particularly with the Filshie Clip System and significant sales drops to PendoTECH, a key customer.
Additionally, foreign exchange risks, increased litigation costs and competitive pressures could further impact UTMD’s financial performance, potentially leading to market share erosion. Nevertheless, a strong balance sheet with $89.2 million in cash and no debt as of June 30, 2024, providing flexibility for strategic investments, acquisitions, or shareholder returns.
The global medical devices market is growing, with UTMD well-positioned to benefit due to its diverse product portfolio in obstetrics, gynecology, neonatal care and blood pressure monitoring. The company’s disciplined cost management reduced COGS and operating expenses, supporting financial stability. UTMD’s focus on niche markets offers strategic advantages, although it.
(You can read the full research report on Utah Medical Products here >>>)
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Investment Research
Vice President Kamala Harris will take her first media interview since becoming the Democratic Party’s nominee for president in the 2024 election.
What Happened: Harris and her vice-presidential running mate, Minnesota Gov. Tim Walz, are set to be interviewed by CNN's Chief Political Correspondent Dana Bash. The interview will air on CNN at 9 p.m. ET on Thursday.
The interview could help define Harris’ policies and where the Democratic nominee stands on key voter issues.
In her acceptance speech at the Democratic National Convention, Harris called for unity and a new direction forward. The presidential candidate covered national security, foreign relations and abortion rights as some of the key topics during her acceptance speech.
Before that, Harris shared details on her "opportunity economy" with calls for tax cuts, lowering costs and building more houses for middle-class Americans.
Did You Know?
Why It Matters: This will be Harris and Walz’s first joint interview with a mass media company since securing the Democratic Party nomination.
It’s also Harris’ first on-the-record sit down with a journalist since President Joe Biden dropped out of the race on July 21. Although Harris has answered questions from reporters at several campaign events and sat for interviews at the DNC with content creators.
Republican vice-presidential candidate J.D. Vance has been outspoken about Harris' lack of media interviews.
"I think it's really disgraceful, both for Kamala Harris but also for a lot of the American media that participates in this stuff, to have a person who has been the presumptive nominee of the Democrat Party for 17 days and refuses to take a single question from the American media," Vance said earlier this month.
According to Politico, Harris often interacts with pool reporters who travel with her on the campaign, but typically speaks “off the record.”
So far, the Harris-Walz ticket raised $540 million since its launch, with both candidates showing a lead over Donald Trump and Vance in many 2024 election polls.
What’s Next: Harris and Trump will meet in a highly anticipated presidential debate on Sept. 10, to be hosted by Walt Disney Company‘s ABC News team. The debate has been a hot topic in recent weeks with the candidates disagreeing on the rules in place.
Other media networks are also pushing for future debates between Harris and Trump.
The first presidential debate, hosted by CNN, set viewership records for parent company Warner Bros. Discovery . It also became a key moment in the election cycle, as it was one of the events that led to calls for Biden to step down.
Check This Out:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Wednesday, August 28, 2024
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. , AstraZeneca PLC and The Walt Disney Co. , as well as two micro-cap stocks FitLife Brands, Inc. and Utah Medical Products, Inc. . The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Visa have gained +4.6% over the year-to-date against the Zacks Financial Transaction Services industry’s gain of +7.9%. The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving its revenues. Visa, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth.
The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
However, elevated operating expenses pose margin challenges. It is witnessing a volatile cash volume from the Asia Pacific and CEMEA regions. Consumer spending growth is also drying up. Moreover, rising client incentives will affect its adjusted revenues. As such, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
AstraZeneca’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+32.3% vs. +29.1%). The company has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.
AstraZeneca’s pipeline is strong, with important late as well as mid-stage pipeline data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets.
Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. By 2030, it expects to generate $80 billion in total revenues. However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit.
(You can read the full research report on AstraZeneca here >>>)
Shares of Walt Disney have outperformed the Zacks Media Conglomerates industry over the year-to-date period (+0.3% vs. +0.1%). The company’s third-quarter fiscal 2024 results reflect growth in Disney+ subscribers and theme park and resort businesses.
Recent attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Park in Paris, as well as the Zootopia theme land at Shanghai Disney, are expected to boost the prospects of the theme park business.
At the same time, the company’s declining ad revenues due to fewer impressions have been a headwind for some time now. Disney+’s profitability is expected to be hurt by higher investments in content, which will also increase programming and production costs in the Media and Entertainment Distribution segment. Its leveraged balance sheet remains a concern. Disney+ is facing tough competition from the likes of Netflix and Amazon Prime Video.
(You can read the full research report on Walt Disney here >>>)
FitLife Brands’ shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+74.5% vs. +12.7%). This microcap company with market capitalization of $152.62 million have witnessed 14.7% year-over-year revenue increase in second-quarter 2024, driven by a 17.5% rise in wholesale and 13.3% in online sales.
Strategic acquisitions and a shift to online channels, now two-thirds of revenue, boosted margins to 44.8%. Key acquisitions like Mimi’s Rock and MusclePharm contribute to growth, with MusclePharm revenues up 27.3% sequentially and Mimi’s Rock’s gross margin at 48.2%, though integration risks remain. The company’s low net debt of $11.7 million supports financial flexibility.
However, challenges include declining legacy brand revenues, a 2.2% drop in the MRC segment, and heavy reliance on online sales, posing risks if e-commerce trends shift. High debt and competition in a saturated market also pose concerns.
(You can read the full research report on FitLife Brands here >>>)
Shares of Utah Medical Products have underperformed the Medical - Products industry over the past six months (-0.2% vs. +7.0%). This microcap company with market capitalization of $236.34 million is facing challenges from declining revenues, particularly with the Filshie Clip System and significant sales drops to PendoTECH, a key customer.
Additionally, foreign exchange risks, increased litigation costs and competitive pressures could further impact UTMD’s financial performance, potentially leading to market share erosion. Nevertheless, a strong balance sheet with $89.2 million in cash and no debt as of June 30, 2024, providing flexibility for strategic investments, acquisitions, or shareholder returns.
The global medical devices market is growing, with UTMD well-positioned to benefit due to its diverse product portfolio in obstetrics, gynecology, neonatal care and blood pressure monitoring. The company’s disciplined cost management reduced COGS and operating expenses, supporting financial stability. UTMD’s focus on niche markets offers strategic advantages, although it.
(You can read the full research report on Utah Medical Products here >>>)
Other noteworthy reports we are featuring today include Sony Group Corp. , BP p.l.c. and Canadian National Railway Co. .
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Visa Rides On Growing Cross Border Volume, Expenses High
Key Drugs Aid AstraZeneca Sales; Pipeline Strong
Disney Banks on Disney+, Theme Parks Business Growth
Featured Reports
SONY Rides on Solid Demand From Music & G&NS Businesses
Per the Zacks analyst, momentum in the Game & Network Services and Music segments cushions Sony's performance. It remains wary of FX volatility and the possibility of an economic downturn in the U.S.
Dividends & Buyback Aid Canadian National , Expenses Ail
The Zacks analyst likes the shareholder-friendly measures adopted by Canadian National. However, rising operating expenses are concerning as they are likely to keep the bottom line under pressure.
Kimberly-Clark Benefits From Gross Supply Chain Productivity
Per the Zacks analyst, Kimberly-Clark is taking robust steps to lower costs. Through the first half of 2024, the company has generated approximately $250 million in gross supply chain productivity.
BFS Tool Aids Builders FirstSource , Low Margin Ails
Per the Zacks analyst, Builders FirstSource benefits from its new BFS digital Tool and a strong value-added product portfolio. Yet, weakening multi-family housing market is denting margins.
Penumbra Rides on Thrombectomy Sales, Global Growth
Penumbra's Thrombectomy growth globally is an upside. Per the Zacks analyst, differentiated technologies of Lightning Flash 2 and Lightning Bolt 7 leading to strong patient outcomes is a key driver.
Rezdiffra Sales Boosts Madrigal , Narrow Pipeline a Woe
Per the Zacks Analyst, the approval of Rezdiffra for NASH is a huge boost for Madrigal ensuring a regular revenue stream. However, the lack of a deep pipeline is a woe.
Operational Efficiency Aids Silgan Amid Low Prices
Per the Zacks analyst, Silgan is gaining from a disciplined capital allocation model and a strong operational performance. Lower prices will hurt its top line.
New Upgrades
BP's Robust Upstream Portfolio To Boost Production Capacity
Per the Zacks analyst, BP's portfolio of upstream projects continues to grow with the beginning of major projects like Seagull. However, its significant reliance on debt capital raises concern.
Sprouts Farmers' Omnichannel Offering to Propel Sales
Per the Zacks analyst, Sprouts Farmers' ability to deliver a seamless omnichannel experience enhances customer loyalty. E-commerce sales rose 30% in the second quarter, representing 14% of net sales.
SM Energy's Robust Eagle Ford & Permian Presence Aids
Per the Zacks analyst, SM Energy's strategic expansion in Texas, particularly in the Permian and Eagle Ford regions, signals growth, leveraging its assets to capitalize on crude price uptrends.
New Downgrades
Weak Industrial Segment and Increasing Costs Ail Barnes
Per the Zacks analyst, Barnes is experiencing softness in the Industrial unit due to softness in the motion control solutions and automation businesses. High costs are an added concern.
Elevated Expenses Likely to Mar Atlassian's Margins
Per the Zacks analyst, increased investment toward enhancing sales & marketing capabilities and higher spending on research & development are likely to dampen Atlassian's margins in the near term.
Macerich Hurt by Tenant Bankruptcies & E-Commerce Adoption
Per the Zacks Analyst, MAC's performance is likely to be affected by tenant bankruptcies, growing adoption of online shopping and substantial geographic concentration of assets.n
Zacks Investment Research
Adds analyst comment, context of deal in paragraphs 12, 14
By Aditya Kalra and Nandan Mandayam
BENGALURU, Aug 28 (Reuters) - Walt Disney Co DIS.N and Reliance Industries RELI.NS won approval on Wednesday for an $8.5 billion merger of their Indian media assets after assuaging regulatory worries about their grip on broadcasting rights for cricket, India's favourite sport.
The Competition Commission of India (CCI) said the deal had been approved subject to modifications submitted voluntarily by the companies, without sharing further details. A detailed order will be issued in coming days, clearing what was seen as the biggest hurdle for the deal.
To get the merger over the line, the two companies have offered concessions, including a commitment to not raise advertising rates unreasonably for streamed cricket matches, and to sell 7-8 non-sports TV channels, a source familiar with the matter said.
The merger will create India's biggest entertainment player to compete with Sony 6758.T, Netflix NFLX.O and Amazon AMZN.O with 120 TV channels and two streaming services.
It will also giveReliance owner Mukesh Ambani, Asia's richest person, a stronger hold on the $28 billion media and entertainment sector. The regulatory nod comes a day before Ambani is set to address Reliance shareholders at its Annual General Meeting.
After asking Reliance and Disney around 100 questions related to the merger, the CCI raised concerns the new entity would control most cricket rights for TV and streaming in India, and could hurt advertisers.
Cricket has a fanatical following in India, the world's most populous country with an estimated 1.4 billion people.
Reliance and Disney have spent roughly $9.5 billion in recent years for TV and streaming rights for the world's richest cricket tournament, the Indian Premier League, the International Cricket Council's matches such as the one-day and T20 World Cups, and matches organised by the Indian cricket board.
The companies also pledged not to bundle and sell advertising slots for different cricket tournaments, and keep subscription rates for their offerings under regulatory limits, the source added.
Neither Reliance nor Disney immediately responded to requests for comment.
Both companies have offered free viewing of cricket matches over the years to attract users to their streaming platforms in the hope they will then buy subscriptions.
Karan Taurani, an analyst at India's Elara Capital said the deal should close within six months as it still needs approval from an Indian companies tribunal, which is expected to be granted.
Disney and Reliance's merged entity will also own Indian broadcast rights for the Wimbledon tennis championship, MotoGP and the English Premier League, among other sporting events.
For an interactive version of this graphic: https://reut.rs/49yL83p
Jefferies has said the Disney-Reliance entity will have a 40% share of the Indian advertising market in the TV and streaming segments.
Companies spent nearly $2 billion in India in 2023 on sports industry related sponsorship, endorsement and media, media agency GroupM estimates, with cricket accounting for 87% of the spend.
Reliance RELI.NS will be the majority owner of the merged company, which will be chaired by Ambani's wife Nita Ambani, who has experience in the arts and ties with Bollywood.
K.K. Sharma, a former head of mergers at the CCI, has said the deal, if approved, would create "a big fish in the broadcasting market" which will practically be a "monopoly on cricket advertisement revenues".
(Additional reporting by Munsif Vengattil; Editing by Varun H K and Barbara Lewis, Kirsten Donovan)
(( Nandan.Mandayam@thomsonreuters.com ; Mobile: +91 9591011727; ))
Keywords: DISNEY-RELIANCE/INDIA (UPDATE 4, PIX)
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.